Features of the Lipid Profile in Patients after Acute Pulmonary Embolism
K. R. Dorokhina,
O. M. Khromtsova,
M. I. Fominykh,
Y. G. Bozhko,
E. V. Kudryavtseva,
V. V. Bazarny,
L. G. Polushina https://doi.org/10.52420/umj.24.4.55
EDN: JJJTYK
Abstract
Introduction. The question of the effect of lipids on the risk of venous thromboembolism (VTE) currently remains open and debatable. The effect of dyslipidemia on the risk of arterial and venous thrombosis is currently being studied.
The aim of the work was to evaluate the parameters of the blood lipids of patients with pulmonary embolism (PE) in the acute period and 1 year after the episode.
Materials and methods. A prospective cohort study of lipids — total cholesterol (TCH), low-density lipoproteins (LDL-C), high-density lipoproteins (HDL-C), triglycerides (TG), apolipoproteins A1and B (ApoA1 and ApoB) — was conducted in patients in the acute period PE and after 1 year of follow-up.
Results. Patients with PE in the acute period have initially normal levels of THC, LDL-C, TG, ApoA1, ApoB, and low levels of HDL-C. After 1 year of follow-up, the levels of THC, LDL-C, TG, and ApoB exceed normal values, dyslipidemia is detected due to the predominance of LDL-C, and HDL-C levels return to normal.
Discussion. Determination of the blood lipids initially and over time allows monitoring changes in the concentration of lipids and correcting dyslipidemia to reduce cardiovascular risk.
Conclusion. In the acute period of PE, normal levels of THC, LDL-C, TG, ApoA1, ApoB are noted, but lower in comparison with patients without a history of VTE, low levels of HDL-C. After a year of follow-up, hypercholesterolemia, dyslipidemia due to LDL-C, TG, and ApoB are detected, which creates a cardiovascular risk in these patients and requires correction.
About the Authors
K. R. Dorokhina
Ural State Medical University; Central City Hospital No. 7
Russian Federation
Competing Interests:
Russian Federation
Kseniia R. Dorokhina — Assistant of the Department of Hospital Therapy, Institute of Clinical Medicine, Ural State Medical University; Cardiologist of the Cardiology Department, Central City Hospital No. 7.
Ekaterinburg
Competing Interests:
None
O. M. Khromtsova
Ural State Medical University; Central City Hospital No. 7
Russian Federation
Competing Interests:
Russian Federation
Oksana M. Khromtsova — Doctor of Sciences (Medicine), Associate Professor, Associate Professor of the Department of Hospital Therapy, Institute of Clinical Medicine, Ural State Medical University; Therapist of the Therapeutic Department, Central City Hospital No. 7.
Ekaterinburg
Competing Interests:
Oksana M. Khromtsova is an editorial council member, and she did not participate in reviewing the material or making a decision about its publication.
M. I. Fominykh
Ural State Medical University; Central City Hospital No. 7
Russian Federation
Competing Interests:
Russian Federation
Maria I. Fominykh — Candidate of Sciences (Medicine), Associate Professor of the Department of Hospital Therapy, Institute of Clinical Medicine, Ural State Medical University; Rheumatologist of the Therapeutic Department, Central City Hospital No. 7.
Ekaterinburg
Competing Interests:
None
Y. G. Bozhko
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Yakov G. Bozhko — Candidate of Sciences (Medicine), Associate Professor of the Department of Polyclinic Therapy, Institute of Clinical Medicine, Ural State Medical University.
Ekaterinburg
Competing Interests:
None
E. V. Kudryavtseva
Ural Institute of Healthcare Management named after A.B. Blokhin
Russian Federation
Competing Interests:
Russian Federation
Elena V. Kudryavtseva — Doctor of Sciences (Medicine), Associate Professor, Professor of the Department Obstetrics and Gynecology, Ural Institute of Healthcare Management named after A.B. Blokhin.
Ekaterinburg
Competing Interests:
None
V. V. Bazarny
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Vladimir V. Bazarny — Doctor of Sciences (Medicine), Professor, Head of the Department of General Pathology and Histological Laboratory, Central Research Laboratory, Director of the Institute of Fundamental Medicine, Ural State Medical University.
Ekaterinburg
Competing Interests:
Vladimir V. Bazarnyi is an editorial board member of Ural Medical Journal, and he did not participate in reviewing the material or making a decision about its publication.
L. G. Polushina
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Larisa G. Polushina — Candidate of Sciences (Medicine), Head of the Central Research Laboratory, Institute of Fundamental Medicine, Ural State Medical University.
Ekaterinburg
Competing Interests:
None
References
1. García Raso A, Ene G, Miranda C, Vidal R, Mata R, Llamas Sillero MP. Association between venous thrombosis and dyslipidemia. Medicina Clinica. 2014;143(1):1–5. DOI: https://doi.org/10.1016/j.medcli.2013.07.024.
2. Robertson L, Broderick C, Yeoh SE, Stansby G. Effect of testing for cancer on cancer — or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database of Systematic Reviews. 2021;(10):010837. DOI: https://doi.org/10.1002/14651858.CD010837.pub5.
3. Mi Y, Yan S, Lu Y, Liang Y, Li C. Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis. Medicine. 2016;95(32):4495. DOI: https://doi.org/10.1097/MD.0000000000004495.
4. Delluc A, Lacut K, Rodger MA. Arterial and venous thrombosis: What’s the link? A narrative review. Thrombosis Research. 2020;191:97–102. DOI: https://doi.org/10.1016/j.thromres.2020.04.035.
5. Zabczyk M, Ariens RA, Undas A. Fibrin clot properties in cardiovascular disease: From basic mechanisms to clinical practice. Cardiovasclular Research. 2023;119(1):94–111. DOI: https://doi.org/10.1093/cvr/cvad017.
6. Lonnberg F, Roos A, Farm M, Heurlin A, Okas M, Gigante B, et al. Causes of death after first time venous thromboembolism. Thrombosis Journal. 2024;22(1):13–16. DOI: https://doi.org/10.1186/s12959-024-00586-8.
7. Kunutsor SK, Mäkikallio TH, Kauhanen J, Voutilainen A, Laukkanen JA. Lipoprotein(a) is not associated with venous thromboembolism risk. Scandinavian Cardiovascular Journal. 2019;53(3):125–132. DOI: https://doi.org/10.1080/14017431.2019.1612087.
8. Kowalski J, Jedrzejczyk JT, Barylski M. Value of D-dimer and HDL cholesterol concentrations in predicting the occurrence of acute pulmonary embolism. Polski Merkuriusz Lekarski. 2016;40(239):283–287. PMID: https://pubmed.gov/27234856.
9. Mengjin H, Xiaosong L, Yuejin Y. Causal associations between cardiovascular risk factors and venous thromboembolism. Seminars in Thrombosis and Hemostasis. 2023;49(7):679–687. DOI: https://doi.org/10.1055/s-0042-1760335.
10. Nielsen LB, Moestrup SK. Lipids metabolism: Lipids and lipoproteins — effect on blood clotting and risk of venous thrombosis. Current Opinion in Lipidology. 2006;17(1):89–91. DOI: https://doi.org/10.1097/01.mol.0000199811.23849.38.
11. van Schouwenburg IM, Mahmoodi BK, Gansevoort RT, Muntinghe FL, Dullaart RP, Kluin-Nelemans HC, et al. Lipid levels do not influence the risk of venous thromboembolism. Thrombosis and Haemostasis. 2012; 108(5):923–929. DOI: https://doi.org/10.1160/TH12-06-0426.
12. Chen F, Peng D, Xia Y, Sun H, Shen H, Xia M. Identification of oxylipins and lipid mediators in pulmonary embolism. Lipids in Health and Disease. 2024;23(1):325–330. DOI: https://doi.org/10.1186/s12944-024-02315-6.
13. Karataş MB, Güngör B, İpek G, Çanga Y, Günaydın ZY, Onuk T, et al. Association of serum cholesterol levels with short-term mortality in patients with acute pulmonary embolism. Heart, Lung and Circulation. 2016; 25(4):365–370. DOI: https://doi.org/10.1016/j.hlc.2015.09.005.
14. Podlipaeva AA, Mullova IS, Pavlova TV, Ushakova EV, Duplyakov DV. New biological markers for diagnosing and predicting the risk of death in patients with pulmonary embolism. Russian Journal of Cardiology. 2020;25(S4):4202. (In Russ.). DOI: https://doi.org/10.15829/1560-4071-2020-4202.
15. Bryk AH, Natorska J, Ząbczyk M, Zettl K, Wiśniewski JR, Undas A. Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties. Journal of Proteomics. 2020;229:103946. DOI: https://doi.org/10.1016/j.jprot.2020.103946.
16. Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K. Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? Atherosclerosis. 2018;271:223–231. DOI: https://doi.org/10.1016/j.atherosclerosis.2018.02.035.
17. Goldhaber SZ. Obesity and pulmonary embolism: Can we dismantle the “obesity paradox”. Thrombosis and Haemostasis. 2024;124(1):58–60. DOI: https://doi.org/10.1055/a-2187-0966.
18. Zhang Z, Rodriguez M, Zheng Z. Clot or not? Reviewing the reciprocal regulation between lipids and blood clotting. Arteriosclerosis, Thrombosis and Vascular Biology. 2024;44(3):533–544. DOI: https://doi.org/10.1161/ATVBAHA.123.318286.
19. Belaj K, Hackl G, Rief P, Eller P, Brodmann M, Gary T. Changes in lipid metabolism and extension of venous thromboembolism. Annals of Nutrition and Metabolism. 2014;64(2):122–126. DOI: https://doi.org/10.1159/000360484.
20. Morelli VM, Lijfering WM, Rosendaal FR, Cannegieter SC. Lipid levels and risk of recurrent venous thrombosis: Results from the MEGA follow-up study. Journal Thrombosis and Haemostasis. 2017;15(4):695–701. DOI: https://doi.org/10.1111/jth.13640.
21. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112(6):893–899. DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.521344.
22. Siudut J, Ząbczyk M, Wołkow P, Polak M, Undas A, Jawień J. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein. Vascular Pharmacology. 2022;144:106977. DOI: https://doi.org/10.1016/j.vph.2022.106977.
23. Labudovic D, Kostovska I, Tosheska Trajkovska K, Cekovska S, Brezovska Kavrakova J, Topuzovska S. Lipoprotein(a) — link between atherogenesis and thrombosis. Prague Medical Report. 2019;120(2–3):39–51. DOI: https://doi.org/10.14712/23362936.2019.9.
24. Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al. The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation. 2020; 141(20):1600–1607. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046397.
25. Izmozherova NV, Popov AA, Kuryndina AA, Gavrilova EI, Shambatov MA, Bakhtin VM. Analysis of pharmacotherapy of arterial hypertension in multimorbid patients. Ural Medical Journal. 2025;24(1):7–25. (In Russ.). DOI: https://doi.org/10.52420/umj.24.1.7.
26. Farmakis IT, Christodoulou KC, Hobohm L, Konstantinides SV, Valerio L. Lipid lowering for prevention of venous thromboembolism: A network meta-analysis. European Heart Journal. 2024;45(35):3219–3227. DOI: https://doi.org/10.1093/eurheartj/ehae361.
Supplementary files
Review
For citations:
Dorokhina KR, Khromtsova OM, Fominykh MI, Bozhko YG, Kudryavtseva EV, Bazarny VV, Polushina LG. Features of the Lipid Profile in Patients after Acute Pulmonary Embolism. Ural Medical Journal. 2025;24(4):55–66. (In Russ.) https://doi.org/10.52420/umj.24.4.55. EDN: JJJTYK
Views:
48
Email this article 